Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LT-002-158 in Healthy Adult Volunteers
NCT06082323Phase 1Completed
- Sponsor
- Leadingtac
- Start
- Jun 2024
- Primary completion
- Nov 2025
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LT-002 in hidradenitis suppurativa (HS) and atopic dermatitis (AD) (3 arms), sponsored by Leadingtac. Primary endpoint: Safety and tolerability of LT-002-158 up to 28 days. Started Jun 2024; status: completed.
02
Drugs
LT-002
03
Conditions
hidradenitis suppurativa (HS)atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06082323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06082323.